Purpose A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapyinduced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancer patients' quality of life (QOL). A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)'s usual practice demonstrates a high incidence (45 %) of CINV, despite premedication with short-acting 5-HT 3 -serotonin-receptor antagonists (5-HT 3 -RAs). National Comprehensive Cancer Network (NCCN)'s evidence-based guidelines recommend the combination of the long-acting 5-HT 3 -RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58 %) to antiemetic guidelines may have explained our high CINV incidence. Methods One-sample binomial test, quasi-experimental design, evaluated a combination intervention that included a provider education session; implementation of riskassessment tool with computerized, standardized antiemetic guideline order sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order set adherence rate. Secondary outcomes included nausea/vomiting rates and QOL. Results Adherence to ordering MEC guideline antiemetics increased significantly, from 58 % to a sustained 90 %, with associated improvement in nausea/vomiting. In acute and delayed phases, 75 and 84 % of patients, respectively, did not experience CINV. There was no significant change in QOL. Conclusion Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/vomiting control and preserved QOL in patients with malignant gliomas.
Introduction
Glioblastoma is the most lethal type of brain tumor, with a poor median survival of 14.6 months despite standard therapy consisting of surgery, radiotherapy, and concurrent adjuvant chemotherapy [1] . Therefore, quality of life (QOL) through symptom management remains an important goal in the care of these patients. Chemotherapy-induced nausea and vomiting (CINV) rank as the most disturbing side effect of cancer therapy and impact QOL negatively [2] . Studies suggest providers underestimate the incidence of delayed CINV (occurring >24-120 h post-treatment) and, thus, inadequately manage CINV [3] [4] [5] . Poorly controlled CINV depletes resources and compromises compliance to treatment, leading to decreased treatment efficacy [4] . Duke University's Preston Robert Tisch Brain Tumor Center (PRTBTC) treats approximately 2,000 individuals with gliomas annually. Six physicians and eight advanced practice providers (APPs) make the choices regarding the antiemetic regimens to control the critical side effect of CINV. Providers primarily premedicated with short-acting 5-HT 3 -serotonin-receptor antagonist (5-HT 3 -RA) antiemetics, which effectively prevent acute CINV (occurring within 24 h post-treatment). However, a major limitation of promising moderately emetic chemotherapy (MEC) regimens administered within the PRTBTC was the associated high incidence (45 %) of CINV or low (55 %) complete response (CR) rate [6, 7] .
In an effort to transform PRTBTC's practice culture and better the prevention of both acute and delayed CINV and improve the QOL of glioma patients, we designed a quality improvement project to increase the adherence of antiemetic ordering to the evidence-based National Comprehensive Cancer Network (NCCN) antiemetic guideline for patients treated with MEC. After an education session and implementation of a risk-assessment tool with computerized, standardized order sets, we compared adherence and patient outcomes with historical benchmark and baseline data. After this combination intervention, we predicted that providers would adopt a practice change and choose antiemetic order sets that conform to the NCCN guidelines in order to improve the care of our glioma patients.
Background and significance
Prevention of CINV in cancer patients receiving antineoplastic therapy has improved dramatically due to the advent of new antiemetics. While available antiemetics can prevent 70-80 % of CINV, 60-80 % of patients continue to experience nausea and vomiting [3, 4, [8] [9] [10] .
Short-acting 5-HT 3 -RAs are the most widely used antiemetics in the prevention of acute CINV [4, [11] [12] [13] . However, recently published meta-analyses demonstrate that the newer, long-acting 5-HT 3 -RA palonosetron (PAL) is superior to other first-generation 5-HT 3 -RAs in preventing both acute and delayed CINV; and both agents have similar, minor side effects [14] [15] [16] . When compared to patients receiving short-acting 5-HT 3 -RAs, patients receiving PAL had less nausea (acute-fixed effect: RR=0.86; 95 % CI 0.76, 0.96, P=0.007; delayed: RR=0.85; 95 % CI 0.78, 0.93, P<0.0003) [15] . Patients also had less vomiting (acute-fixed effect: RR=0.79; 95 % CI 0.68, 0.91, P=0.001; delayed RR=0.78; 95 % CI 0.70, 0.87, P<0.00001) [15] . This meta-analysis was the basis for the high-grade, evidence-based NCCN, Multinational Association of Supportive Care in Cancer (MASCC), and American Society of Clinical Oncology (ASCO) antiemetic guidelines for MEC. The NCCN/MASCC/ASCO guidelines currently recommend the combination of PAL ("preferred" 5-HT 3 -RA) and DEX for the prevention of both acute and delayed CINV in MEC [17] . Glioma CINV studies support this NCCN/MASCC/ASCO antiemetic guideline because neurokinin-1 (NK-1)-receptor antagonists interact with standard glioma medications (e.g., dexamethasone; enzyme inducing antiepileptics) [7, 18] . The high quality of evidence and low-risk/benefit ratio support the NCCN/MASCC/ASCO guideline recommendation that PAL plus DEX be incorporated into MEC standard order sets for malignant glioma patients. The NCCN guidelines further recommend assessing CINV risk factors (i.e., female, younger age, low alcohol use, and prior chemotherapy use) and state that a chemotherapy regimen's emetogenic potential is the most significant predictor for CINV [4, 17, 19, 20] . Chemotherapy can range in emetogenicity, with MEC and highly emetogenic agents causing CINV in >30 and >90 %, respectively, of patients treated.
In the fall of 2011, a year's review of computerized order sets generated for patients receiving MEC at the PRTBTC revealed that antiemetic guidelines were followed only 41 % of the time despite PAL availability. The major barrier to guideline adherence was knowledge, with 79 % (11/14) of providers "lacking awareness" of the current antiemetic guidelines. However, education alone does not improve guideline adherence [21, 22] . Studies evaluating strategies for implementing antiemetic guidelines concluded that standardized order sets and audit feedback improve the transferability and sustainability of guidelines into oncology practices [9, 21, 23] . Mertens et al. found that only when adherence feedback was coupled with patient outcomes did nonadherence decrease significantly, from 73 % to a sustained 0 %, yielding reduced overall CINV [21] . Thus, a combination intervention with an audit-feedback strategy that translates evidence into practice was developed to improve the adherence of guideline antiemetic ordering for glioma patients treated with MEC.
Project aims and outcomes
We proposed that the implementation of a combination intervention including (a) an education session, (b) risk assessment tool with (c) computerized standard order sets utilizing the 2012 NCCN/MASCC/ASCO antiemetic guideline would increase adherence to antiemetic guidelines and ultimately improve the CINV CR rate and the QOL of malignant glioma patients. We pursued the following aims:
Primary aim
The primary aim was to determine if the combination intervention would increase provider adherence to the NCCN/MASCC/ ASCO antiemetic guideline for malignant glioma patients treated with MEC from the baseline adherence of 60 to ≥80 %.
Primary outcome The adherence rate was a ratio of the number of MEC orders with PAL/DEX to the total number of MEC orders. That proportion was determined by the aggregated data generated via the computerized ordering system queries.
Secondary aim (1) The first secondary aim was to determine if PAL/DEX can increase the acute and delayed CINV CR rate from 55 to 80 % in malignant glioma patients receiving MEC.
CINVoutcomes Acute CR is the proportion of patients achieving a CR during the first 24 h following chemotherapy administration. Delayed complete CR is the proportion of patients achieving a CR during the delayed period (>24-120 h) following chemotherapy administration. Operational definitions of other secondary outcomes are as follows: (a) CINV CR, absence of nausea/vomiting defined as no emetic episode or use of rescue medication; (b) CIV CR, absence of vomiting episode or the use of vomit medication; and (c) CIN CR, Absence of the use of medication to help nausea or due to concern about the possibility of experiencing nausea. The CINV outcomes were captured via the Osoba survey.
Secondary aim (2)
The second secondary aim was to determine if PAL/DEX will stabilize or improve QOL in malignant glioma patients within 24-120 h of receiving MEC.
QOL outcome in CINV The QOL outcomes were measured via the following valid and reliable instruments: Osoba survey (Cronbach's α=0.85), the Functional Assessment of Cancer Therapy-Brain (FACT-BR), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-fatigue) surveys (Cronbach's α=0.95) [24] [25] [26] [27] [28] . The 10-item Osoba patientreported survey addressed the impact of nausea and vomiting on daily functioning. The 50-item FACT-BR measured general QOL and glioma symptoms across five subscales [26, 27] . The 13-item FACIT-fatigue has clinical meaningfulness if there is a ±3.0 change in scores from baseline [28] . Surveys took 10-15 min to complete.
Methods

Study design
A single-arm, quasi-experimental study design was utilized to compare post-implementation adherence rates to baseline and historical control data to determine changes in the adherence and patient outcomes. This project involved the collection and review of de-identified aggregated data and, thus, the study was exempted by the institutional review board at Duke University.
Setting
This project took place at the PRTBTC adult outpatient clinic, where six physicians and eight APPs order antiemetics via Duke's computerized ordering system. The majority of providers were female (64 %, 9/14), with a median of 6.5 years of experience (range, 1-31). Half of the providers were trained in neurology, with the other half trained in oncology.
Sample
The innovation targeted the sample of order sets chosen by the PRTBTC providers to measure guideline adherence. We reviewed all orders of the adult malignant glioma patients scheduled to receive intravenous MEC at Duke from September through November 2012 to determine adherence to NCCN/MASCC/ASCO guidelines. The risk assessment tool further divided MEC order sets into three subsets, based on emetogenicity level within the MEC category: (a) low leveltemozolomide (occurs <1 %); (b) medium level-irinotecan/ bevacizumab, carboplatin/bevacizumab, temozolomide/ irinotecan/bevacizumab; and (c) high level-carboplatin/ irinotecan/bevacizumab and methotrexate. As follow-up care, patients who received MEC were asked about their nausea and vomiting experience. Patients who completed surveys and received the guideline antiemetic order sets became the sample for secondary analyses.
Study procedures
A combination intervention consisting of (a) an educational provider training session, (b) a risk assessment alert tool with (c) computerized standard chemotherapy order sets containing the NCCN antiemetics regimen (PAL/DEX) with an auditfeedback strategy was implemented in the fall of 2012. Adherence data via computerized queries were collected by the nurse informaticist at baseline and monthly to account for any practice changes that occurred over time. The historical CINV CR rate was obtained from previous studies. Baseline data describing the current antiemetic practice for adherence, historical CINV CR, and baseline QOL data were used to compare and evaluate the following three post-intervention outcomes: (a) adherence to NCCN/MASCC/ASCO antiemetic MEC guidelines, (b) CINV CR rate, and (c) QOL. Outcomes were evaluated monthly over 3 months to assess adherence trends and to provide audit-feedback, ending by December 2012.
Combination intervention
On August 31, 2012, a 30-min educational session, consisting of a PowerPoint presentation to update providers about the research supporting the new 2012 antiemetic guidelines and additional intervention components, was conducted. A copy of the antiemetic guidelines was given to all providers. At the time of ordering chemotherapy for adult patients with malignant glioma receiving MEC, a risk assessment tool containing a check off of the risk factors was provided [19] . The MEC risk factor then prompted the provider to choose the guideline antiemetic order set. For IV regimens with moderately emetogenic potential, a standardized order set containing the "preferred" antiemetics (PAL 0.25 mg IV and DEX 10 mg IV) was available in the Duke computerized ordering system (Fig. 1) . Patients who receive a MEC regimen routinely are asked risk factors and CINV outcomes and to fill out FACT-BR surveys to report baseline CINV rate, and QOL. Repeat routine care assessments were conducted 24 and 120 h postchemotherapy to assess acute and delayed CINV CR rate and QOL, respectively. To promote awareness, adherence rates and patient outcomes were presented via monthly email/staff meetings.
Data analysis
Descriptive statistics were used to summarize risk factors and emetogenicity level. The primary outcome, adherence to guideline orders, was evaluated historically (over 1 year) and at baseline (over a 3-month period) prior to project implementation. Post-intervention order set adherence rates were then evaluated monthly for 3 months and overall. With 36 anticipated post-intervention orders, a one-sample binomial test comparing historical and post-intervention adherence rates was conducted at the 0.05 level of significance having 80 % power to detect a difference between a 60 and 80 % order set adherence rate (STPLAN version 4.5).
Secondary (patient) outcomes included (a) antiemetic efficacy and (b) QOL in patients receiving the recommended NCCN/MASCC/ASCO antiemetic during acute/delayed phases. Grunberg and Aapro have reported that a change in CINV rate of 10 % is clinically meaningful [29] . With at least 22/36 patient order sets projected to require PAL, a onesample binomial test comparison of the observed CR rate with the historical benchmark of 55 % had at least 80 % power to detect an increase to 82.5 %. Historical and prospective cohorts were compared to determine if CINV risk factors were distributed differentially between cohorts.
Means and standard errors were generated to describe FACT-BR/FACIT-fatigue/QOL pre-and post-intervention. For the FACT-BR/FACIT-fatigue, a linear mixed model that accounted for within-patient correlation assessed the relationship between time and outcome. Cronbach's alpha was computed for each subscore. A Wilcoxon signed-rank test assessed whether QOL as measured by the Osoba subscales had changed from baseline.
Results
Outcomes of this project were (a) the adherence rates to the antiemetic guideline order sets and (b) the patient outcomes (CINV CR rates; QOL) associated with receiving guideline antiemetics.
Adherence
Baseline adherence over 3 months was 58 % (with a historical adherence of 41 % over a 1-year period). A total sample of 61 MEC order sets was reviewed for monthly and overall adherence. Monthly adherence to the NCCN/MASCC/ASCO antiemetic guideline gradually increased from 58 to 88 %, and, ultimately, to 92 %, with a sustained and significant increase in the overall adherence rate to 90 % (55/61; 95 % CI 80, 96; P<0.05), as demonstrated in Fig. 2 . Adherence at baseline and during monthly follow up for all patients, as well as the subset of MEC regimens defined by emetogenicity level, is summarized in Table 1 . Within the MEC treatment group, adherence increased from 44 to 100 % in high-level MEC regimens, whereas in medium-level MEC regimens, adherence increased from 77 to 84 %. No patients received low-level intravenous temozolomide.
Patient characteristics/risk factors
Risk factors for the 36 surveyed patients are shown in Table 2 . Thirty-two of those patients received the guideline antiemetic. The majority (95 %) of patients who received guideline antiemetics have ≥3 risk factors, including prior CINV (75 %) and low alcohol intake (100 %).
Nausea and vomiting
There was a significant and meaningful clinical increase in both the acute CINV CR rate of 75 % (95 % CI 57, 89; P<0.05) and the delayed CINV CR rate of 84 % (95 % CI 67, 95; P<0.05). The CINV, CIN, and CIV CR rates increased significantly and are presented in Table 3 . Table 4 presents the mean score at baseline for each of the FACT-BR/FACIT-fatigue subscales and during the acute/delayed phases. There was no evidence of a statistically significant change over time in QOL. Cronbach's alpha ranged between 0.67 and 0.9 for these subscales. However, there was a meaningful clinical 3.0-point increase in fatigue, as defined by Cella, during the acute phase [28] . Osoba survey results showed no significant change in vomiting on the impact of daily function. There was a significant increase in nausea on the impact of daily function during the acute and delayed phases (P=0.001, P= 0.0005, respectively). The median, third quartile, and maximum increase in nausea are 0, 0.4, and 1.6 for the acute phase, and 0, 0.5, and 1.8 for the delayed phase. This statistically significant change is not considered clinically significant given that only three patients had more than a 1-unit change in nausea score.
Quality of life
Discussion
Multiple studies have demonstrated that providers mismanage CINV, but evidence-based methods to increase adherence to Fig. 2 Monthly adherence to antiemetic guideline: 1 adherence was 41 % over a 1-year period 6 months prior to implementation; 2 adherence was 58 % over a 3-month baseline period to match project period antiemetic guideline ordering and ultimately improve CINV are limited [3] [4] [5] 30] . Our project showed that a combination intervention and audit-feedback strategy designed to translate evidence into an oncology practice significantly increased and sustained guideline adherence from 58 to 90 %, while improving both acute and delayed CINV CR rates to 75 and 84 %, respectively.
Implications for practice
A survey by Grunberg et al. [10] indicated that providers accurately predict acute vomiting but underestimate nausea and delayed CINV, since patients are often sent home without assessment of delayed CINV risk. Our combination intervention assessed and ameliorated both acute and delayed CINV.
However, the lower CIN CR rates (acute, 84 %; delayed, 88 %) and higher CIV CR rates (acute, 91 %; delayed, 97 %) suggest that nausea was less controlled and may not be a pre-symptom of vomiting or relieved by the same pre-antiemetic. Furthermore, while patients reported nausea, they did not consistently use a rescue antiemetic, emphasizing that nausea measurement is subjective. These findings are supported by studies which suggest that nausea is more associated with anorexia than with vomiting and should be managed with non-pharmacological and nutritional interventions. Trial literature has combined the nausea and vomiting constructs into one dichotomous endpoint, but future designs should separate these two endpoints to better understand these different phenomena.
Burmeister et al. [30] demonstrated that guideline nonadherence is related to under-or overdosing of antiemetics, especially in the delayed setting. Tendes and colleagues [32] recommend that a CINV reduction score based on the actual antiemetic dose ordered may better evaluate guideline prescribing. We found that computerized, standardized order sets containing the accurate antiemetic dose and frequency are an effective method both to prevent guideline antiemetic under/overdosing and reduce acute/delayed CINV. This finding is supported by studies, emphasizing that computerized ordering can enhance adherence [33, 34] .
Risk assessments demonstrated that 95 % of our glioma patients were at a ≥60 % risk for developing CINV, which (17) a CINV chemotherapy-induced nausea and vomiting, MEC moderately emetic chemotherapy CR complete response; CIV chemotherapy-induced vomiting; CIN chemotherapy-induced nausea; CINV chemotherapy-induced nausea and vomiting; CIV CR absence of vomiting episode or the use of vomit medication; CIN CR absence of the use of medication to help nausea, or due to concern of the possibility of experiencing nausea; CINV CR absence of nausea or vomiting defined as no emetic episode or use of rescue medication a Historical data demonstrated a 55 % CINV CR rate alerted providers and may have influenced their antiemetic choice [35] . Yet, a regimen's emetogenic potential is the most significant predictor of CINV and may be the primary predictor of adherence [4, 17, 19, 20] . Our combination intervention changed providers' antiemetic ordering practices, particularly for the patients receiving "high-emetogenicity level" MEC regimen, where adherence increased from 44 to 100 %. Informal diffusion of adherence (41 to 58 %) occurred with increased awareness of antiemetic research prior to project implementation. The knowledge barrier relating to the current antiemetic guidelines was mitigated by an educational session. However, studies have shown that increasing knowledge alone will not transform practice. We agree with Burmeister, who stated that Mertens' [21] audit-feedback strategy of reporting adherence rates coupled with patient outcomes to antiemetic prescribers can drive change toward ordering antiemetic guidelines. We demonstrated that transformational and sustainable adherence practices can be achieved through this combination intervention and evidence-based audit-feedback strategy. Overall adherence increased to 90 % (95 % CI 80, 96). To monitor and ensure sustainability, our nurse informaticist can periodically query the adherence rate of computerized order sets, and the educational session can be re-implemented if future adherence falls below the limits of this confidence interval.
Limitations
While adherence improved significantly, thereby decreasing CINV, it is important to note that the analyses do not account for the lack of independence among orders (e.g., orders being from the same providers and patients). Additionally, the project focused on a glioma population, limiting generalizability to other cancers. We recognize that another limitation is computerized ordering availability at other institutions. While pre/postintervention groups had similar CINV risks, use of historical control data to assess CINV rates in a nonrandomized design is a limitation. Selection bias exists in secondary patient outcomes, as some patients who received the intervention did not fill out the CINV survey. This project was not powered to demonstrate QOL improvement but suggest that the appropriate antiemetics did not decrease QOL. Further studies are needed to assess QOL associated with guideline adherence.
Conclusion
Well-designed, rigorous studies support the NCCN/MASCC/ ASCO antiemetic guidelines for administering PAL/DEX before MEC to prevent CINV. A major limitation of promising glioma regimens is the associated high CINV rate due to the low concordance with the recent antiemetic guidelines. The combination of the educational session; risk-assessment tool; and computerized, evidence-based antiemetic order sets was found to be an effective decision support intervention to increase antiemetic guideline adherence. Adding the strategy of monthly audit feedback of adherence with patient outcomes increased and sustained guideline adherence. Our combination intervention and audit-feedback strategy allowed for successful adherence and translation of evidence into our oncology practices, which ultimately improved CINV in patients with gliomas.
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